Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Reported Basic Consolidated EPS Of $-3.9588 For Period Ended 2015-12-31

0

The annual basic consolidated EPS for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for the period ended 2015-12-31 was $-3.9588. On quarterly basis, the basic consolidated EPS reading for the quarter ended 2015-12-31 was $-3.9588.

EPS from continuing operations

Coming to basic EPS from continuing operations, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $-3.9588 for the annual period ended 2015-12-31. Quarterly basic EPS from continuing operations for the three-month period ended 2015-12-31 stood at $-3.9588.

EPS contribution from parent

For the annual period ended 2015-12-31, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received basic EPS of $-3.9588 from its parent company. On quarterly basis, basic EPS contribution from the parent company for the period ended 2015-12-31 was $-3.9588.

Basic net EPS

For the annual period ended 2015-12-31, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported basic net EPS of $-3.96. On quarterly basis, the company’s basic net EPS for the three-month period ended 2015-12-31 stood at $-3.96.

Consolidated diluted EPS

The annual consolidated diluted EPS reading for the period ended 2015-12-31 stood at $-3.9588. For the quarter ended 2015-12-31, consolidated diluted EPS was $-3.9588.

Basic diluted EPS

On annual basis, diluted EPS reading from continuing operation was $-3.9588 for the period ended 2015-12-31. Diluted EPS from continuing operations for the quarter ended 2015-12-31 was $-3.9588.

Net diluted EPS

Net diluted EPS reading for the annual period ended 2015-12-31 was $-3.96. For the quarterly period ended 2015-12-31, net diluted EPS was $-3.96.

Diluted EPS from parent

From the parent company, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received diluted EPS of $-3.9588 for the annual period ended 2015-12-31. On quarterly basis, diluted EPS contribution from the parent for the quarter ended 2015-12-31 was $-3.9588.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted net basic EPS reading of $-3.96 for the annual period ended 2015-12-31. For the quarter, basic net EPS of $-3.96 was for the quarter ended 2015-12-31.

Net diluted EPS for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for the annual period ended 2015-12-31 was $-3.96. The company also reported net diluted EPS reading of $-3.96 for the quarter ended 2015-12-31.

The annual average basic shares outstanding for the period ended 2015-12-31 is 36.783 while for the quarter ended 2015-12-31 is 36.783.

The diluted shares outstanding for the fiscal year ended is 2015-12-31 is 36.783 while for the quarter ended 2015-12-31 is 36.783.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 8 times, 1 visits today)